Neuropathic pain is caused by damage or disease to the central or peripheral nervous system. It is a major health burden and poorly managed due to a lack of efficacious analgesics (1) (2) (3) . Current pharmacotherapies, including opioids, anti-epileptics and antidepressants, have low efficacy and significant side effects (4, 5) . Therefore, there is a clinical need to develop novel drug leads to better treat neuropathic pain.
Conotoxins (toxins isolated from the venom of marine cone snails) target a wide variety of membrane receptors and ion channels, and are a rich source of potential therapeutic agents. α-Conotoxins are small peptides that typically range in size from 12-19 amino acids, contain two disulfide bonds and usually have an amidated C-terminus. α-Conotoxin Vc1.1, a synthetic derivative of a peptide derived from the venom of the marine cone snail Conus victoriae, potently suppresses signs of pain when injected intramuscularly near the site of injury in rat models (6) (7) (8) , demonstrating its potential as an analgesic therapeutic. RgIA, an α-conotoxin from Conus regius, has also been shown to significantly reduce chronic constriction nerve injury-induced hyperalgesia in rats (9, 10) .
How α-conotoxins Vc1.1 and RgIA relieve neuropathic pain remains controversial. Both are highly potent antagonists of α9α10 nicotinic acetylcholine receptors (nAChR) 4 (9-11), and Vc1.1 antagonizes the nicotine-induced increase in axonal excitability of unmyelinated C-fibers (12) . Therefore, α9α10 nAChRs were proposed as the target for Vc1.1 and RgIA to mediate analgesia in chronic and neuropathic pain models (10) . However, several structural analogs of Vc1.1 retain activity at α9α10 nAChRs, but lose their anti-allodynic effect (13, 14) . This suggests that a target other than α9α10 nAChR may contribute to the pain-relieving activity of α-conotoxins. Recent studies show that the analgesic α-conotoxins Vc1.1 and RgIA potently inhibit N-type calcium channel currents in rat sensory neurons (8, 15, 16) . Pharmacological studies further reveal that Vc1.1 doesn't interact directly with voltage-gated calcium channels (VGCC), but via a voltage-independent, G protein-coupled GABA B receptor-mediated mechanism (8, 15) . Collectively, these findings indicate that several different membrane receptors, including the GABA B receptor, may contribute to the pain-relieving activity of a class of α-conotoxins.
To date, there is a lack of molecular studies confirming the interaction between α-conotoxins and GABA B receptor subunits, and demonstrating the need for functional GABA B receptor dimers for Ca v 2.2 channel inhibition by α-conotoxins. The present study examines whether or not a functional GABA B receptor is needed to link analgesic α-conotoxins and Ntype VGCC current inhibition.
We took two different approaches to this study. First, we investigated VGCC currents in isolated rat dorsal root ganglion (DRG) neurons following transient knockdown of the GABA B receptor subunit expression using small interfering RNA (siRNA). Second, we investigated Ca v 2.2 channel modulation by Vc1.1 in HEK 293 cells stably expressing Ca v 2.2 channels and transient transfection with both subunits of the human GABA B receptor. These approaches showed that GABA B receptor expression is necessary for the observed inhibition of N-type VGCCs by the α-conotoxins Vc1.1 and RgIA. A preliminary report of some of these results has been presented in abstract form.
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EXPERIMENTAL PROCEDURES
DRG neuron preparation -DRG neurons were enzymatically dissociated from ganglia of 4-to 14-day-old Wistar rats according to standard protocols. Briefly, rats were killed by cervical dislocation, as approved by the RMIT University Animal Ethics committee, and the spinal cord removed. Ganglia of all areas of the spinal cord were collected in ice cold Hank's Balanced Salt Solution (Invitrogen). They were incubated in 1 mg/mL collagenase (Sigma) in Hank's Balanced Salt Solution for 30 min at 37ºC, transferred to warm Neurobasal media (Invitrogen), and then triturated using a firepolished Pasteur pipette to obtain a cell suspension. The suspension was centrifuged at 400 g for 5 min and immediately used for transfection.
siRNA Double-labeling immunocytochemistry and confocal microscopy -Immunocytochemistry was performed on transfected DRG neurons 2-4 days after transfection. DRG neurons were fixed in 4% paraformaldehyde for 15 min at room temperature. After two washes with PBS, the cells were pre-incubated in blocking solution (10% goat serum, 1% Triton X-100 in PBS) for 30 min at room temperature, followed by overnight incubation at 4ºC with anti-β-IIItubulin and either polyclonal anti-GABA B1 or monoclonal anti-GABA B2 antibodies in fresh blocking solution. After 2 washes with PBS, the fluorophore-conjugated secondary antibodies were applied for 1.5 h at room temperature. Cell nuclei were counterstained with DAPI. After 4 more washing steps with PBS, the cells were sealed with fluorescence mounting media (Dako, Glostrup, Denmark). Control experiments determining the specificity of the immunocytochemical procedures were validated by omitting the primary antibodies. Images were acquired using a Nikon A1 laser-scanning confocal microscope equipped with a Plan Apo VC 60x water-immersion objective, an Argon laser (488 nm), a solid state laser (561 nm) and NIS Elements software using the same settings for siRNA-transfected and control cells.
Quantitative analysis of GABA B receptor protein levels -DRG cells, immunolabeled as described above, were subjected to quantitative analysis of GABA B R1 receptor protein levels using a high-content imaging system (ImageXpress Micro, Molecular Devices, Sunnyvale, CA). Cells transfected with the siRNAs targeting the GABA B R1 and R2 subunits were compared with cells transfected with the non-targeting negative control siRNA. For each siRNA treatment group, 756 sites (each containing an average of 3.3 neurons) were scanned. Neurons were identified by βIII-tubulin expression. A threshold for R1 fluorescence was set at above background or nonspecific staining levels. All βIII-tubulin-positive cells with abovethreshold fluorescence were counted as high R1-expressing neurons. A difference in the percentage of high R1-expressing neurons between control and knockdown of GABA B R1 and GABA B R2 (R1+R2 KD) cell batches would indicate successful knockdown. Moreover, to detect subtle differences in expression between high R1-expressing neurons of the control and R1+R2 KD cell batches, we further evaluated R1-fluorescence intensities indicating protein expression levels by dividing the sum of the grayscale intensity of R1 fluorescence by the total βIII-tubulin stained area.
DRG and HEK 293 cell electrophysiology -DRG neurons were transfected with either GABA B receptor-specific siRNAs or negativecontrol siRNA, and grown on poly-D-lysinecoated glass cover slips for 1-4 days. Only DRG neurons exhibiting green fluorescence, due to co-transfection of the fluorescein-labeled oligonucleotide, were selected for electrophysiological recordings. Cells were transferred into a small-volume (∼300 μL) recording chamber, constantly perfused with a solution containing (in mM) tetraethylammonium (TEA)-Cl 140, BaCl 2 2, Dglucose 10 and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 10, pH 7.4 (with NaOH). The internal pipette solution contained (in mM) CsCl 140, MgCl 2 1, MgATP 5, Na-GTP 0.1, bis(2-aminophenoxy)ethane-N,N,N',N'-tetra-acetic acid (BAPTA)-Cs 4 5 and HEPES 10, pH 7.3 (with CsOH). Whole-cell Ba 2+ currents were elicited from a holding potential of -80 mV, by 0.05-Hz, 200-ms step depolarizations to +10 mV. In each experiment, R1+R2 KD neurons and control neurons from the same batch of DRG preparation and transfection were tested successively. They were included for analysis only if the VGCC inward current inhibition in the R1+R2 KD neuron by baclofen was at least 10% less than the current inhibition by baclofen in the control neuron, indicating successful knockdown of the GABA B receptor.
HEK 293 cells stably expressing human Ca v 2.2 channels (α 1B , α 2 δ1 and β 3 subunits) were transiently co-transfected with cDNAs encoding human GABA B R1 (10 μg), human GABA B R2 (10 μg) (OriGene Technologies, Inc., Rockville, MD) and enhanced green fluorescent protein (1 μg) (a reporter gene construct), using calcium phosphate precipitation (17) . They were then cultured at 37
• C. In some experiments, cDNAs encoding the human dopamine receptor 2 (DRD2; OriGene Technologies) were used instead of GABA B R1 and R2. Patch-clamp experiments were carried out 4-6 days after transfection, using the wholecell recording configuration. HEK 293 cells were superfused with a solution containing (in mM) BaCl 2 10, CsCl 85, TEA-Cl 40, MgCl 2 1, D-glucose 10 and HEPES 10, with pH 7.4 (with TEA-OH). Fire-polished borosilicate patch pipettes (2-3 MΩ tip resistance) were filled with a solution containing (in mM) Csmethenesulphonate 108, EGTA 9, MgCl 2 4, MgATP 2, Na 2 GTP 0.5 and HEPES 9, pH 7.2 (with CsOH). Typically, cells were voltageclamped at −80 mV and membrane currents were elicited by 0.1-Hz, 150-ms step depolarizations to −10 mV.
Recordings were carried out using a Multiclamp 700B amplifier (Molecular Devices), controlled by a Clampex9.2/ DigiData1332 acquisition system at room temperature (23-25°C). Membrane currents were filtered at 2 kHz and sampled at 5 or 8 kHz.
Leak and capacitative currents were subtracted using a −P/4 pulse protocol. Data were stored digitally on a computer for further analysis. Peak current amplitude in response to the depolarizing pulse was measured once a steady state was achieved (~ 5-10 min). Current densities were calculated by dividing the normalized current amplitude by the cell capacitance measured immediately before the recording. Current amplitudes obtained in the presence of the drug were normalized by dividing by the current amplitude obtained under control conditions. Chemicals and drugs -α-Conotoxins Vc1.1, RgIA and AuIB were synthesized as described previously (18) (19) (20) (21) and provided as a stock concentration in H 2 O of ~ 1 mM by Dr RJ Clark (University of Queensland). The ω-conotoxins CVID and MVIIA were prepared as described previously (22 Statistical analysis -Numerical data are presented as mean ± standard error of the mean. The statistical significance between two groups was evaluated by Student's unpaired t-test. The statistical significance between three or more groups was evaluated by one-way ANOVA followed by Bonferroni's post-hoc test. Values of P < 0.05 were considered to be statistically significant. All statistical analyses were achieved using Prism Version 5.1 (GraphPad Software Inc., La Jolla, CA).
RESULTS
Knockdown of GABA B receptor mRNA expression in DRG neurons -To effectively knockdown the expression of functional GABA B receptors (which are heterodimers of the two GABA B subunits R1 and R2), we tested siRNAs targeting either the R1 or the R2 subunit in isolated DRG neurons. qRT-PCR showed that following 24-48 h post-transfection, the mRNA levels of R1 in cells transfected with a R1-specific siRNA significantly decreased to 32.6 ± 3.5% (n = 4) of control cells transfected with a scrambled, non-targeting siRNA (P < 0.0001) (Fig. 1A) . R2 mRNA levels 24-48 h after transfection with the R2-specific siRNA were significantly reduced to 53.9 ± 8.0% (n = 4) of control (P = 0.0073) (Fig. 1B) . A further increase in siRNA concentration (300 nM) didn't lead to a further knockdown of either GABA B receptor subunit (data not shown). The scrambled, non-targeting siRNA-transfected control cells exhibited R1 and R2 expression levels almost identical to mock transfected (H 2 O transfected) cells (Fig. 1A, B) . This indicated that there was not a nonspecific effect due to the siRNA transfection process itself.
No off-target effects of the GABA B subunittargeting siRNAs were observed, because expression of the housekeeping genes, analyzed in parallel, was unaffected by the addition of siRNAs. Furthermore, when mRNA expression of a single GABA B receptor subunit was disrupted by siRNA, the expression level of the other subunit was not affected (Fig. 1A, B) , indicating target-specific knockdown. Cotransfection of the R1-and R2-targeting siRNAs (R1+R2 KD) demonstrated that knockdown of each subunit was equally effective compared with single-subunit knockdowns without interference (33.6 ± 6.1%, n = 5; P < 0.0001 mRNA levels of R1, and 53.4 ± 13.3%, n = 5; P = 0.0265 mRNA levels of R2, respectively) (Fig.  1A, B) . Given that hetero-dimerization of R1 and R2 subunits is essential for functional GABA B receptors (23), we used the cotransfection protocol in the following experiments, expecting more effective knockdown.
GABA B receptor protein knockdown by siRNA treatment -Immunofluorescence labeling of GABA B receptors in rat DRG neurons and visual inspection by confocal microscopy revealed an apparent decrease in fluorescence intensities for GABA B R1 and GABA B R2 in R1+R2 KD neurons compared with scrambled, non-targeting siRNA-transfected DRG neurons ( Fig. 2A, B) . The difference in intensity of R1 immunostaining was quantified using a highcontent imaging system. In these experiments, we focused on R1 immunofluorescence because R2 immunofluorescence intensity and specificity were not as high as that of R1. The analysis revealed that the percentage of cells with R1-specific immunofluorescence above the set threshold was significantly lower in the R1+R2 KD group (35.1 ± 3.6%, n = 6) compared with control cells (57.3 ± 1.2%, n = 6; P = 0.0002) (Fig. 3B) . Furthermore, the fluorescence intensities of R1, which indicate expression levels, in cells with above-threshold R1 fluorescence were 20.2 ± 5.4% lower in knockdown cells compared with control cells (n = 6; P = 0.0206) (Fig. 3C) . Taken together, the above data demonstrated that GABA B receptor knockdown by siRNA effectively decreases GABA B receptor protein expression in DRG neurons.
Impairment of α-conotoxin-mediated inhibition of VGCC currents by GABA B receptor knockdown -R1+R2 KD DRG neurons were used in patch-clamp experiments to characterize the activity of the GABA B receptor agonist baclofen and α-conotoxins Vc1.1 and RgIA. Control and R1+R2 KD neurons exhibited comparable VGCC currents upon depolarization to +10 mV from a holding potential of -80 mV (Fig. 4 A, B) . There was no significant difference in VGCC peak current density between control (-72.2 ± 8.2 pA/pF, n = 13) and R1+R2 KD (-51.3 ± 9.1 pA/pF, n = 13) DRG neurons. The effect of Vc1.1 on VGCC current amplitude in control and R1+R2 KD neurons was examined by bath application of Vc1.1 (100 nM), followed by the application of baclofen (30 µM).
Of 7 neurons that exhibited efficient functional knockdown of GABA B receptors, VGCC current amplitude was inhibited by 29.5 ± 4.2% in response to bath application of baclofen. However, control DRG neurons exhibited a baclofen-induced decrease of 45.6 ± 3.7% (n = 7, P = 0.0136) (Fig. 4A-C) . The remaining VGCC current was not further inhibited by bath application of the selective Ntype VGCC antagonist, ω-conotoxin CVID (300 nM) (data not shown). Bath application of 100 nM Vc1.1 to control neurons inhibited the VGCC current amplitude by 20.9 ± 3.7% (n = 7) (Fig. 4A, D) . However, in R1+R2 KD neurons, the effect of Vc1.1 on the VGCC current was significantly impaired, with the current amplitude reduced only by 5.2 ± 4.7% (n = 7, P = 0.0223) (Fig. 4B, D and Table 1 ). Note that in all neurons of the R1+R2 KD treatment group in which baclofen-mediated inhibition of VGCCs was impaired, Vc1.1-induced inhibition of VGCC currents decreased in all cases. The decrease in the number of functional GABA B receptors, caused by siRNA knockdown, resulted in a functional disruption of GABA B negative coupling to VGCCs. This confirms that Vc1.1, similar to baclofen, acts on N-type VGCCs via the GABA B receptor.
The disruption of VGCC current inhibition by GABA B receptor knockdown was more pronounced for Vc1.1-mediated N-type VGCC inhibition than for baclofen-mediated inhibition. In R1+R2 KD neurons, N-type VGCC current inhibition by Vc1.1 was 75.1% less than the current inhibition by Vc1.1 in control neurons, whereas baclofen-mediated inhibition decreased by only 35.4% (n = 7) in these cells. In all of the 13 R1+R2 KD neurons tested with baclofen, the current inhibition decreased by 41.4%, compared with the 13 corresponding control neurons (Table 1) . Although the present findings substantiate previous reports that baclofen and Vc1.1 both act via the GABA B receptor (15, 16) , the greater decrease in Vc1.1-mediated inhibition, caused by siRNA-mediated GABA B receptor knockdown, suggests that the two compounds may act via different downstream signaling cascades.
We also evaluated the activity of α-conotoxins RgIA and AuIB on the GABA B receptor in knockdown and control DRG neurons. RgIA (100 nM) reduced peak VGCC current amplitude in control neurons by 16.2 ± 3.0% (n = 4) ( Table 1 ) which is consistent with previous studies showing RgIA activity on untransfected DRG neurons (14, 15) . In contrast, R1+R2 KD neurons considerably decreased RgIA-mediated inhibition, with a reduction of current amplitude by 3.0 ± 3.2% (n = 4; P = 0.0245) ( Table 1) . AuIB (100 nM), an analgesic α-conotoxin active at the α3β4 nAChR (20) and GABA B receptor (8) , also inhibited VGCC current amplitude in control neurons, whereas in R1+R2 KD cells, inhibition of the VGCC current amplitude significantly decreased (n = 3, data not shown). Together, these experiments show that the activity of these α-conotoxins on N-type VGCCs is dependent on GABA B receptor expression.
To demonstrate that the siRNA knockdown of the GABA B receptor was specific, control experiments examined the effect of µ-opioid receptor agonists on VGCC currents in transfected DRG neurons. Activation of µ-opioid receptors by agonists, such as Met-enkephalin and DAMGO, have been shown to inhibit the Ntype VGCC current via activation of a pertussistoxin sensitive G protein-coupled receptor (24, 25) . Similar to these findings, we observed a wide variation in the sensitivity of individual DRG neurons to DAMGO, with some neurons almost non-responding. The different sensitivities corresponded to different populations of DRGs, because the isolated neurons originated from ganglia of all regions along the spinal cord. As neurons studied were chosen at random, any statistical difference in VGCC current inhibition between R1+R2 KD and control neurons would suggest an effect of the knockdown on µ-opioid receptor signaling. However, we did not observe any statistically significant difference in the inhibition of VGCC currents by 1 µM DAMGO between R1+R2 KD neurons (18.9 ± 5.2%, n = 5; P = 0.3083) and scrambled, non-targeting siRNA-transfected control neurons (12.5 ± 2.8%, n = 5) ( Table 1 ). This result confirmed that the impairment of VGCC current inhibition by baclofen, Vc1.1, RgIA and AuIB in GABA B knockdown neurons was a result of decreased GABA B receptor expression, rather than nonspecific effects of the GABA B receptor-targeting siRNAs.
Reconstitution of the human GABA B receptor signaling pathway in HEK 293 cells -To demonstrate that both subunits of the human GABA B receptor are needed to inhibit Ca v 2.2 channels with α-conotoxin Vc1.1, we reconstituted the GABA B receptor signaling pathway in HEK 293 cells stably expressing Ca v 2.2 channels (Ca v 2.2 cells). This was done by co-transfecting cDNAs of cloned human GABA B receptor subunits (R1 and R2) (Fig. 5) .
In HEK 293 cells with Ca v 2.2 alone (control), peak Ba 2+ currents were not affected by α-conotoxin Vc1.1 (200 nM). However, the selective N-type (Ca v 2.2) VGCC inhibitor, ω-conotoxin MVIIA (200 nM), almost completely inhibited the inward Ba 2+ current (Fig. 5A) . In cells expressing Ca v 2.2 and co-transfected with GABA B R1 and R2 (Ca v 2.2+R1+R2 cells), Vc1.1 and baclofen caused inward Ba 2+ current inhibition, indicated by the decrease of peak current amplitude during the administration of these compounds (Fig. 5B, C) . Similarly, α-conotoxin Rg1A (200 nM) inhibited inward Ba 2+ current only in Ca v 2.2+R1+R2 cells (data not shown). However, the effect of Vc1.1 (200 nM) or baclofen (100 μM) was absent in Ca v 2.2 cells transiently transfected with the dopamine receptor D2 (data not shown). In Ca v 2.2+R1+R2 cells, the inhibition of Ca v 2.2 channels by Vc1.1 could be blocked by the selective GABA B receptor antagonist CGP55845 (Fig. 5C ). In Ca v 2.2+R1+R2 cells, Vc1.1 and baclofen caused 40 ± 7% (n = 5) and 65 ± 5% (n = 7) inhibition of the depolarization-activated inward Ba 2+ current amplitude, respectively, whereas in Ca v 2.2, Ca v 2.2+R1, or Ca v 2.2+R2 cells, inhibition of the Ba 2+ current was not observed (Fig. 5D) . In summary, these data demonstrate that functional expression of both R1 and R2 subunits are needed for the inhibition of Ca v 2.2 channels by Vc1.1 in the heterologous HEK 293 cell expression system.
DISCUSSION
This study demonstrates that functional GABA B receptors are needed to observe the analgesic α-conotoxins Vc1.1 and RgIA decrease N-type VGCC peak current amplitude. While previous pharmacological studies showed that Vc1.1 and RgIA can inhibit VGCC currents in rodent DRG neurons via activation of the G protein-coupled GABA B receptor (8, 15, 16) , there were no molecular studies showing the need for expression of both GABA B receptor subunits.
We chose a knockdown approach to demonstrate dependence of α-conotoxin activity on GABA B receptor expression, because RNAi is a powerful tool for the investigation of molecular signaling cascades and siRNAs have already been successfully used for knockdown of GABA B receptor subunits (26) (27) (28) and other target receptors and ion channels in pain pathways (29, 30) . In siRNA knockdown experiments, we show that the inhibition of Ntype VGCC currents in rat DRG neurons by α-conotoxins decreased following a transient knockdown of GABA B receptors. The effectiveness of the siRNA knockdown was underscored by qRT-PCR and immunocytochemistry, showing a decrease in GABA B receptor mRNA and protein expression, respectively.
Results from the GABA B receptor knockdown study were reinforced by a complementary approach using HEK 293 cells. These cells represent an established expression system for various membrane proteins (receptors and ion channels) and have been used to study signaling of heterologously expressed GABA B and other G protein-coupled receptors (14, 31 Our electrophysiological findings on GABA B receptor knockdown show that in control DRG neurons, the effect of Vc1.1 and RgIA on N-type VGCC currents was substantially less than that of baclofen. Moreover, Vc1.1 and baclofen clearly differed in their susceptibility to GABA B receptor knockdown. Inhibition of N-type VGCC currents in GABA B knockdown DRG neurons by Vc1.1 was almost completely abolished. In contrast, even though the effect of baclofen was significantly impaired, inhibition of VGCC current was still observed. These observations corroborate previous findings, indicating that Vc1.1 and baclofen act on N-type VGCCs via different pathways, both involving the GABA B receptor (15) . N-type VGCCs can be inhibited by two distinct G protein-dependent inhibitory pathways: voltage-dependent and voltage-independent (32). Voltage-dependent inhibition is the most common pathway, involving Gβγ binding directly to the α-subunit of the N-type VGCC (33, 34) . The inhibition of N-type VGCCs in DRG neurons by α-conotoxin Vc1.1 is voltage-independent and activates a pathway that involves src tyrosine kinase (15) . The GABA B receptor agonist baclofen and its inhibition of VGCC currents is well characterized (35) (36) (37) and appears to inhibit Ntype VGCC currents predominately via the voltage-dependent pathway (32) . These results suggest that the Vc1.1-mediated, voltageindependent pathway is more sensitive to GABA B receptor knockdown (partial knockdown) than the baclofen-mediated, voltage-dependent pathway.
Our findings not only strengthen the pharmacological significance of the observed Ntype VGCC inhibition by α-conotoxins, Vc1.1 and RgIA, but extend them to show that these α-conotoxins are active at human GABA B receptors. In vivo studies have shown that Vc1.1, RgIA and AuIB administered intramuscularly in rats can potently suppress neuropathic pain following partial nerve ligation (6) (7) (8) . To date, there are at least five α-conotoxins which inhibit N-type VGCCs in DRG neurons and the three that have been tested in animal pain models are analgesic. Further studies of the structureactivity relationships are likely to identify the specific residues that confer potency and selectivity for the GABA B receptor, and will improve understanding of how α-conotoxins act on the GABA B receptor. In future, other α-conotoxins and analogues activating the GABA B receptor may be discovered, making the human GABA B receptor a novel target for drugs used to treat neuropathic pain. FIGURE LEGENDS FIGURE 1. GABA B receptor mRNA knockdown by siRNA treatment in rat DRG neurons. Transfection of siRNA (100 nM) targeting GABA B receptor subunits GABA B R1 (R1 KD) and GABA B R2 (R2 KD) resulted in a knockdown by 67 ± 3% (n = 4) of R1 (A) and a knockdown by 46 ± 8% (n = 4) for R2 mRNA levels (B), respectively, compared with a negative control in which cells were transfected with an equal concentration of a scrambled, non-targeting siRNA. Co-transfection of R1-and R2-targeting siRNAs (R1+R2 KD) resulted in knockdown levels similar to single subunit knockdowns (66 ± 6%, and 47 ± 13%, respectively; n = 5). The mRNA levels were determined by qRT-PCR, calculated by comparative quantitation analysis and normalized to the expression levels of water transfected cells (*P < 0.05 and ***P < 0.0001 versus control). FIGURE 2. GABA B receptor immunofluorescence is reduced in GABA B knockdown DRG neurons as observed using confocal microscopy. Immunolabeling of DRG neurons and visual inspection by confocal microscopy revealed an apparent decrease in fluorescence intensities for GABA B R1 and GABA B R2 in neurons transfected with siRNAs to disrupt GABA B R1 and R2 expression, when compared with scrambled, non-targeting siRNA-transfected DRG neurons. Cells were immunostained 3 days after transfection, using antibodies directed against R1 (green) (A), or against R2 (green) (B). Immunostaining of βIII-tubulin is shown in red. Representative images are shown. Scale bars represent 50 µm. 
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